These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 8319977)

  • 21. A recombinant hybrid outer membrane protein for vaccination against Pseudomonas aeruginosa.
    Knapp B; Hundt E; Lenz U; Hungerer KD; Gabelsberger J; Domdey H; Mansouri E; Li Y; von Specht BU
    Vaccine; 1999 Mar; 17(13-14):1663-6. PubMed ID: 10194820
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Current status of Pseudomonas aeruginosa vaccine.
    Michelim L; Medeiros GS; Zavascki AP
    Curr Pharm Biotechnol; 2013; 14(11):951-9. PubMed ID: 24372247
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Immunogenic properties and specificity of pseudomonas aeruginosa polyvalent vaccine].
    Schiller B; Lysakowska E; Owczarska K
    Med Dosw Mikrobiol; 1981; 33(2):91-6. PubMed ID: 6170849
    [No Abstract]   [Full Text] [Related]  

  • 24. Protective efficacy of recombinant exotoxin A--flagellin fusion protein against Pseudomonas aeruginosa infection.
    Farajnia S; Peerayeh SN; Tanomand A; Majidi J; Goudarzi G; Naghili B; Rahbarnia L
    Can J Microbiol; 2015 Jan; 61(1):60-4. PubMed ID: 25496361
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mucosal vaccination with a recombinant OprF-I vaccine of Pseudomonas aeruginosa in healthy volunteers: comparison of a systemic vs. a mucosal booster schedule.
    Göcke K; Baumann U; Hagemann H; Gabelsberger J; Hahn H; Freihorst J; von Specht BU
    FEMS Immunol Med Microbiol; 2003 Jul; 37(2-3):167-71. PubMed ID: 12832121
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A live-attenuated Pseudomonas aeruginosa vaccine elicits outer membrane protein-specific active and passive protection against corneal infection.
    Zaidi TS; Priebe GP; Pier GB
    Infect Immun; 2006 Feb; 74(2):975-83. PubMed ID: 16428743
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The first clinical trial of immuno's experimental Pseudomonas aeruginosa flagellar vaccines.
    Crowe BA; Enzersberger O; Schober-Bendixen S; Mitterer A; Mundt W; Livey I; Pabst H; Kaeser R; Eibl M; Eibl J
    Antibiot Chemother (1971); 1991; 44():143-56. PubMed ID: 1801633
    [No Abstract]   [Full Text] [Related]  

  • 28. [Pseudomonas aeruginosa preparations for active immunization].
    Nazarchuk LV
    Vrach Delo; 1991 Jul; (7):22-7. PubMed ID: 1771827
    [No Abstract]   [Full Text] [Related]  

  • 29. Protective effects of affinity-purified antibody and truncated vaccines against Pseudomonas aeruginosa V-antigen in neutropenic mice.
    Moriyama K; Wiener-Kronish JP; Sawa T
    Microbiol Immunol; 2009 Nov; 53(11):587-94. PubMed ID: 19903258
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pseudomonas aeruginosa. II. Experimental acellular vaccine of an endotoxin and anatoxin type.
    Bĕlohlávek S; Pavlík V; Rencová J; Stránský V; Nováková L; Sourek J; Výmola F
    J Hyg Epidemiol Microbiol Immunol; 1987; 31(3):343-52. PubMed ID: 3119704
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vaccination promotes TH1-like inflammation and survival in chronic Pseudomonas aeruginosa pneumonia. A new prophylactic principle.
    Johansen HK; Cryz SJ; Hougen HP; Moser C; Høiby N
    Behring Inst Mitt; 1997 Feb; (98):269-73. PubMed ID: 9382750
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synthetic peptide vaccine and antibody therapeutic development: prevention and treatment of Pseudomonas aeruginosa.
    Cachia PJ; Hodges RS
    Biopolymers; 2003; 71(2):141-68. PubMed ID: 12767116
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Protective immunization against chronic Pseudomonas aeruginosa pulmonary infection in rats.
    Klinger JD; Cash HA; Wood RE; Miler JJ
    Infect Immun; 1983 Mar; 39(3):1377-84. PubMed ID: 6404823
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vaccination for Pseudomonas aeruginosa.
    Alexander JW; Fisher MW
    Am J Surg; 1970 Oct; 120(4):512. PubMed ID: 4990276
    [No Abstract]   [Full Text] [Related]  

  • 35. Heterologous Pseudomonas aeruginosa O-antigen delivery using a Salmonella enterica serovar Typhimurium wecA mutant strain.
    Bridge DR; Whitmire JM; Makobongo MO; Merrell DS
    Int J Med Microbiol; 2016 Nov; 306(7):529-540. PubMed ID: 27476047
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Protective efficacy of Pseudomonas aeruginosa type-A flagellin in the murine burn wound model of infection.
    Faezi S; Safarloo M; Amirmozafari N; Nikokar I; Siadat SD; Holder IA; Mahdavi M
    APMIS; 2014 Feb; 122(2):115-27. PubMed ID: 23758581
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Experimental studies on the protective efficacy of a Pseudomonas aeruginosa vaccine.
    Stanislavsky ES; Edvabnaya LS; Bandman OA; Boolk VF; Zhvanetskaya MI; Vargina AK
    Vaccine; 1989 Dec; 7(6):562-6. PubMed ID: 2514518
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunization with a chimeric tobacco mosaic virus containing an epitope of outer membrane protein F of Pseudomonas aeruginosa provides protection against challenge with P. aeruginosa.
    Staczek J; Bendahmane M; Gilleland LB; Beachy RN; Gilleland HE
    Vaccine; 2000 Apr; 18(21):2266-74. PubMed ID: 10717347
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Immunization with Bifidobacterium bifidum-vectored OprI vaccine of Pseudomonas aeruginosa enhances inhibitory effect on P. aeruginosa in mice].
    Liu X; Li W
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2017 Aug; 33(8):1040-1044. PubMed ID: 28871943
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recombinant OprF-OprI as a vaccine against Pseudomonas aeruginosa infections.
    Baumann U; Mansouri E; von Specht BU
    Vaccine; 2004 Feb; 22(7):840-7. PubMed ID: 15040936
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.